Skip to content

Stock-Based Comp at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$146M+1.4%
CTO
Citius Oncology, Inc.CTOR
$3.53M+68.9%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$2.65M+8.3%
Corvus Pharmaceuticals logo
Corvus PharmaceuticalsCRVS
$2.65M+112%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$8.17M-14.3%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$3.58M+10.3%

Other financials

Income statement

See full
Revenue-
Net income-$7.5M-13.1%
EPS (diluted)-$0.13+13.3%

Balance sheet

See full
Cash & equivalents$6.3M+1.3%
Total debt$456.9K+178%
Total equity$23.2M+135%
Total assets$29.7M+103%

Cash flow

See full
Operating cash flow-$4.4M+6.9%
CapEx$48.8K+14.5%
Free cash flow-$4.5M+6.7%

Valuation

See full
Market cap$155.39M+45.8%
Enterprise value$149.54M+52.3%

Returns & leverage

See full
Return on equity-187.2%
Debt / equity0.0×
Current ratio1.2×-1.8×

Where this comes from

Reported directly by TuHURA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: TuHURA Biosciences, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about TuHURA Biosciences, Inc.'s stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TuHURA Biosciences, Inc.'s stock-based comp?
TuHURA Biosciences, Inc. (HURA) reported stock-based comp of $2.8M in Q1 2026.
How has TuHURA Biosciences, Inc.'s stock-based comp changed year-over-year?
TuHURA Biosciences, Inc.'s stock-based comp increased by 96.3% year-over-year, from $1.42M to $2.8M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.